With the continuous in-depth research on the mechanism of KRAS^G12Cmutations in targeted therapy of non-small cell lung cancer，KRAS^G12Chas evolved from non producible to an important targeted therapy site. The KRAS^G12Cmutation inhibitor has achieved dual progress in efficiency and survival in targeted therapy of non-small cell lung cancer. Although drug resistance is inevitable with treatment，research on drug resistance mechanisms has found that combination medication is one of the ways to overcome or reduce drug resistance.